INBS earnings analysis
What we found in INBS's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
INBS delivered strong top-line momentum, with fiscal 2026 revenue up 38.1% to $4.22 million and gross margin improving to 48.6%, driven overwhelmingly by the United Kingdom. However, operating losses widened to $12.61 million, operating cash use reached $11.93 million, and the auditor and management identified substantial doubt about the company’s ability to continue as a going concern without additional financing. The regulatory-led strategy remains dependent on completing approvals and expanding beyond the UK, while equity issuance and 6.12 million outstanding warrants create significant dilution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated
- Revenue increased 38.1% to $4,215,175 in fiscal 2026 from $3,052,532 in fiscal 2025. Product growth was led by cartridges at $2,485,563, readers at $902,263, and accessories at $827,349.
- Gross margin improved
- Gross profit rose to $2,049,994 from $1,246,859, implying gross margin improvement to 48.6% from 40.9%. Quarterly gross margin also reached 50.5% in 2026Q3, versus 36.7% in 2025Q2.
- UK drives geographic growth
- The United Kingdom generated $4,153,759 of revenue, or approximately 98.5% of the consolidated total, up from $2,868,027. This more than offset declines in APAC, the Americas, and Rest of world, whose combined revenue fell to $61,416 from $184,505.
- Regulatory-led product strategy
- The company describes itself as a medical technology business developing and delivering “intelligent, rapid, non-invasive testing and screening solutions.” Its stated objectives include completing regulatory approval in the U.S. and other markets, expanding into target markets, and continuing product development.
- Capital raised and debt cleared
- Financing provided $14,983,706 of cash in fiscal 2026, including $10,699,794 from common-stock issuance and $4,283,912 from warrant exercises. Cash increased to $3,992,312 from $1,019,909 at year-end.
- Prior control weaknesses remediated
- Management reported that previously identified material weaknesses in internal control over financial reporting were remediated as of June 30, 2026. The CEO and CFO also concluded that disclosure controls were effective at the reasonable-assurance level.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern financing need
- The company reported $12,430,975 of net loss attributable to INBS and $11,927,222 of cash used in operating activities in fiscal 2026. With cash of approximately $3.99 million, management said cash may be insufficient to fund the current operating plan for at least the next 12 months and that additional funds will be required; the filing states this raises substantial doubt about going-concern status.
- Australian grant repayment obligation
- The Australian Government grant acquittal determined that $2,172,108 was owed, of which $1,252,842 remained payable at June 30, 2026. The obligation is included in accounts payable and accrued expenses and could compete with operating and development cash needs.
- Material equity and warrant dilution
- The company had 6,118,293 warrants outstanding at June 30, 2026, all excluded as antidilutive from diluted EPS, compared with 5,508,496 in 2025. Common shares issued and outstanding also increased to 2,905,603 from 732,327, highlighting substantial potential dilution from continued equity financing and warrant exercises.
- Clinical spending and approval risk
- The company remains committed to clinical and regulatory work while operating with limited liquidity. As of June 30, 2026, $1,357,742 remained payable under clinical study agreements, including a $976,538 January 2026 clinical performance study commitment, and management expects operating losses for the foreseeable future.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-8.44
- Gross margin
- 48.6%
- Operating margin
- -299.1%
- Segment
- United Kingdom: $4,153,759 revenue in 2026 versus $2,868,027 in 2025
- Segment
- APAC: $12,467 versus $29,167
- Segment
- Americas: $8,750 versus $22,638
- Segment
- Rest of world: $40,199 versus $132,700
What they said about what is next.
No quantitative revenue or EPS guidance is provided in the 10-K. Management states that objectives include completing regulatory approval, expanding the revenue base into target markets, and continuing product development; the company expects operating losses and does not expect positive operating cash flow in the foreseeable future.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Intelligent Bio Solutions Inc. reported positive revenue growth of 46% year-over-year in Q3 2026, reaching $1,060,802, driven by an increase in customer acquisitions. Despite higher operating expenses leading to a net…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INBS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever